Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Publication

Citation: Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M.: Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther, Volume 327 (1), 2008
Authors: Fujikura H, Fujimori Y, Isaji M., Ishikawa-Takemura Y, Katsuno K, Nakashima I
Journal: J Pharmacol Exp Ther
Year: 2008
DOI: 10.1124/jpet.108.140210
PubMed: 18583547
Machine-readable: REST API RDF